---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Systemic antitumor therapy"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Systemic antitumor therapy. Topics: Chemotherapy and targeted agents for functioning pancreatic neuroendocrine tumors: ENETS 2023 guidance; Cytotoxic chemotherapy and sunitinib in malignant insulinoma: effect on hypoglycemia; Capecitabine-temozolomide, other chemotherapy, and streptozocin in malignant insulinoma: Mayo Clinic cohort; Cabozantinib: labeled indication in pancreatic neuroendocrine tumors; 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/systemic-antitumor-therapy"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Systemic antitumor therapy

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Systemic Antitumor Therapy

<a id="topic-2.2.2.1.8-1"></a>

### Chemotherapy and targeted agents for functioning pancreatic neuroendocrine tumors: ENETS 2023 guidance

> “Systemic treatment with chemotherapy or peptide receptor radionuclide therapy (PRRT) plays a key role for selected patients for both control of tumour growth and hormonal symptoms.”
> “One of the most commonly used chemotherapy regimens is capecitabine associated with temozolomide which had a response rate of 40% in grade 1–2 Pan-NET in a prospective, multicentre, randomised phase II trial.”
> “Historically, streptozotocin is well-known for its diabetogenic effects, making it a suitable alternative for high grade or clinically aggressive insulinomas.”
> “PRRT, chemotherapy, everolimus or sunitinib should generally be reserved for SSA-refractory cases [4, B].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.8-2"></a>

### Cytotoxic chemotherapy and sunitinib in malignant insulinoma: effect on hypoglycemia

> “Historically, (combinations of) 5-fluorouracil, doxorubicin, and streptozotocin have been used for the treatment for inoperable functioning and nonfunctioning pancreatic high-grade NET, including malignant insulinomas”
> “However, these drugs and their combinations cause considerable toxicities.”
> “Again, it can be expected that considerable debulking following chemotherapy will be associated with less frequent and less severe hypoglycemias.”
> “In contrast to everolimus, sunitinib does not directly influence insulin secretion or insulin resistance.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Chemotherapeutic regimes including streptozocin, 5‐fluorouracil, capecitabine and temozolomide (CAPTEM) and cisplatin with etoposide have been used in the management of metastatic neuroendocrine tumour alongside everolimus and somatostatin analogues, though evidence for their independent effect on hypoglycaemia is lacking”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.1.8-3"></a>

### Capecitabine-temozolomide, other chemotherapy, and streptozocin in malignant insulinoma: Mayo Clinic cohort

> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.”
> “In contrast, chemotherapy and streptozocin-based therapies had significantly shorter OS times of 15.23 and 8.35 months, respectively.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.2.2.1.8-4"></a>

### Cabozantinib: labeled indication in pancreatic neuroendocrine tumors

> “CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).”

Source: [Cabometyx prescribing information (2025)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s019lbl.pdf)

<a id="topic-2.2.2.1.8-5"></a>

### Manufacturer statements on tumor-directed therapy and hypoglycemia, insulinoma and NICTH

> “Tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or NICTs.”
> “In many cases, tumor-directed therapies are administered concurrently with medical therapies for hypoglycemia and in other cases successful treatment of hypoglycemia often enables the initiation and/or continuation of tumor-directed therapies, as indicated.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
